October 9, 2026 — scheduled focused research update

Home · Latest · Milestones

Focused review of 32 active condition topics in six groups, with the retained Sleep hub read as inherited history rather than a duplicate monitoring assignment. Searches use the last full successful check plus a seven-day overlap, with preceding ninety-day context for unfinished baselines. New findings below are newly appraised, with their original source dates; older context is labeled baseline. Every incomplete review retains its full-topic successful-check date.

Findings

• 2026-10-01 — Sponsor-reported randomized phase 2 results; conference presentation; publication described as in press: COURAGE reports one-year lean-tissue preservation with low-dose trevogrumab.
• 2026-10-02 — Peer-reviewed randomized sham-controlled trial; accepted early article and abstract: Sham-controlled knee-radiotherapy trial finds a temporary responder benefit.
• 2026-10-08 — Sponsor-only randomized phase 2 topline: FB102 meets a celiac gluten-challenge histology endpoint; clinical detail remains limited.
• 2026-10-02 — Sponsor-reported phase 2 extension and conference data: Litifilimab adds one-year cutaneous-lupus follow-up after placebo crossover.
• 2026-10-08 — Sponsor-reported phase 3 recruitment milestone: SL1002 completes pivotal knee-pain enrollment; readout forecast for Q2 2027.
• 2026-10-09 — Trial-registry recruitment update: Suzetrigine’s long-term diabetic-neuropathy study closes recruitment.
• 2026-10-08 — New human phase 3 trial registration: New randomized knee-replacement study tests suzetrigine’s opioid-sparing effect.
• 2026-10-09 — New human phase 3 trial registration: Tilrekimig registers a recruiting phase 3 severe-asthma trial.
• 2026-10-07 — New randomized human phase 2 trial registration: RSV study compares vaccine strategies after lung or stem-cell transplantation.
• 2026-10-07 — Sponsor-only topline from randomized double-blind placebo-controlled human trial: Petrelintide reports phase 2b weight and HbA1c results in type 2 diabetes.
• 2026-10-07 — Sponsor statement corroborated by recruiting registries; no efficacy results: Petrelintide phase 3 first treatment is confirmed.
• 2026-10-09 — New formal randomized human-trial protocols; not yet recruiting: Oral VK2735 registers the SUNRISE phase 3 trials.
• 2026-10-09 — New phase 1 open-label human-trial registration: New trial studies tolerability when switching from tirzepatide to zenagamtide.
• 2026-10-08 — Informal trial-participant report — unconfirmed: Anonymous SOLIS-1 participant describes vomiting, drowsiness and tremor after dose escalation.
• 2026-10-01 — Peer-reviewed single-centre phase 2 proof-of-principle randomized double-blind placebo-controlled trial: Small randomized senolytic MASH trial reports a biopsy signal and more adverse events.
• 2026-10-08 — Dated sponsor regulatory-filing announcement; review, not approval: FDA accepts finerenone application for chronic kidney disease without diabetes.
• 2026-10-07 — Sponsor-only small open-label single-dose human data plus scheduled primary conference abstract: PYC-003 reports exploratory target engagement in inherited polycystic kidney disease.
• 2026-10-09 — Historical baseline; Live investigator-site status; original launch date unverified: Farabursen phase 3 recruitment is listed at Tufts.
• 2026-09-16 — Historical baseline; Registered phase 4 randomized double-blind sequential trial; baseline recovery, no results: Large pragmatic trial compares commonly used insomnia medicines.
• 2026-09-29 — New investigator randomized open-label comparative-effectiveness protocol; no results: New trial will compare tirzepatide with PAP for apnea treatment effectiveness.
• 2026-09-17 — Historical baseline; Registered phase 3 randomized masked placebo-controlled trial; baseline expansion: Monthly berobenatide is being studied in OSA with PAP.
• 2026-07-09 — Historical baseline; Registered phase 3 randomized-withdrawal trial; older baseline recovery: XYRISE studies expanded Xywav dosing in narcolepsy and idiopathic hypersomnia.
• 2026-05-26 — Historical baseline; Peer-reviewed expert consensus/practice algorithm; historical baseline, not new October trial data: Updated RLS treatment algorithm supplies a current clinical context.
• 2026-10-08 — Historical baseline; Registered phase 2 randomized masked human study; baseline recovery, no results: A placebo-controlled CBD-extract trial is planned for idiopathic RLS.
• 2026-08-21 — Historical baseline; Registered prospective single-arm first-in-indication feasibility study; baseline recovery: An implanted spinal-cord stimulation feasibility study is planned for refractory RLS.
• 2026-10-07 — Sponsor-funded secondary analysis of randomized NHS-Galleri data; national impact is modeled: EDCC poster reports fewer emergency cancer diagnoses with Galleri.
• 2026-10-06 — Sponsor-funded post hoc statistical modeling of randomized screening data: NHS-Galleri model estimates a preclinical detection window.
• 2026-10-07 — Sponsor-funded descriptive conference subgroup analysis: PATHFINDER 2 subgroup analysis leaves uncertainty about equal performance.
• 2026-10-07 — Sponsor-funded uncontrolled retrospective insurance-claims analysis: Claims analysis finds no mammography decline after a negative Galleri result.
• 2026-10-07 — Sponsor-funded descriptive categorization of cancers detected in two existing trials: Galleri poster catalogs histologic cancer types rather than 204 independent screening targets.
• 2026-09-22 — Historical baseline; Verified phase 2 human trial registry; historical baseline gap repair: Baseline recovered: TREMHANCE is recruiting for oral SAR448851.
• 2026-09-18 — Recovered recent randomized phase 2 human trial registration: SAGITTARIUS registers an amyloid vaccine trial before cognitive impairment.
• 2026-09-14 — Recovered recent randomized phase 1 human trial registration: MLS101 registers a low-dose psilocybin trial for PMDD.
• 2026-10-09 — Sponsor-reported FDA approval corroborated by approved U.S. prescribing information; FDA letter not independently retrieved: Teva announces U.S. approval of monthly subcutaneous olanzapine.
• 2026-10-05 — New formal randomized human neuromodulation trial registration: FEAST-AFT registers a focused-seizure-therapy comparison in depression.
• 2026-10-07 — Randomized phase 2/3 trial publication; primary investigator release appraised, full paper inaccessible: NRG-BR002 publication finds no added survival benefit from ablating breast-cancer metastases.
• 2026-10-06 — New formal randomized phase 2 human trial registration: ImmProCure registers a vaccine and bispecific trial for prostate-cancer recurrence.
• 2026-10-06 — New formal phase 2 human trial registration: VA registers a LabVax combination study in advanced lung adenocarcinoma.
• 2026-10-07 — Two new early-phase human trial registrations; no patient results: New GPC3 and MET antibody-drug conjugates enter the human-trial registry.
• 2026-09-28 — Sponsor-reported human phase 2 follow-up and phase 3 enrollment, with October9 registry corroboration: 4D-150 expands into phase 3 for diabetic macular edema.
• 2026-10-08 — Peer-reviewed observational germline sequencing cohort; official journal and investigator reporting appraised: Large cancer cohort finds inherited variants beyond early-onset cases.
• 2026-10-06 — Official investigator announcement of planned prospective human implementation research: Yale plans a 5,000-person primary-care genomic-screening pilot.
• 2026-10-07 — New human pilot registration; no results: SCULPT registers a small placebo-controlled topical fat and cellulite study.
• 2026-10-09 — Sponsor conference poster and supplemental slides; selected Phase 3 extension analysis: Actual BRAVE-AA-PEDS poster shows maintenance among selected adolescent responders.
• 2026-09-22 — Sponsor-submitted registry results; newly appraised older source: PP405 posted Phase 2a results add arm-level safety, without regrowth estimates.
• 2026-10-07 — New human trial registration; no outcomes: Botulinum toxin versus nanofat pattern-hair-loss study enters the registry.
• 2026-06-01 — Historical baseline; Peer-reviewed uncontrolled human series; historical baseline: Recovered baseline: ultrasound laxity series has mixed objective and subjective outcomes.
• 2026-09-27 — Peer-reviewed accepted randomized split-scar trial; abstract-level appraisal: Silicone-tape scar trial reports appearance benefit, with substantial attrition.
• 2026-10-02 — Peer-reviewed within-scar comparative trial; full HTML appraised: Small burn-scar comparison does not establish a clear total-score advantage for botulinum add-on.
• 2026-09-14 — Sponsor commercial forecast with FDA approval cross-check; older source newly recovered: Recovered U.S. filler launch forecasts separate availability from earlier approval.
• 2026-10-08 — New Phase 3 trial registration; no results: Povorcitinib adds a separate registered Chinese Phase 3 vitiligo trial.
• 2026-10-09 — Primary Phase 3 registration plus dated sponsor development statement; no U.S. results: AURORA registry now lists recruitment; sponsor reports sites activated.
• 2026-10-08 — New trial registration; no results: B244 microbiome spray adds a registered Phase 2b acne study.
• 2026-10-09 — New Phase 2 human registration; no results: Small periodontal extracellular-vesicle trial enters the human registry.

Coverage by topic

Whole-body MRI

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: whole body MRI screening HERCULES results October2026 September2026; whole-body MRI October2026 results screening study; Levels whole body MRI healthy people Durand October1 2026

Remaining gaps: Read current topic/state and September5 overlap; all named registry records retrieved using live CT.gov API. HERCULES remains recruiting in an April2025 record; no result posted and its future completion dates remain estimates.; Opened October1 Levels original episode313 full transcript; reappraised October1 JGIM review already saved October6, therefore no duplicate event. New discovery matches were diagnostic/prostate-treatment imaging or unrelated studies, not a qualifying repeated-screening outcome trial.; International registries, long-term outcomes and all imaging-policy changes remain incompletely searched. Prenuvo research-network enrollment statements are undated and were not treated as a dated new milestone.

Informal sources and unresolved claims: Original Levels episode313, October1, DrDanielDurand/Prenuvo CMO with MikeHaney, full transcript now accessible. At52:35 and the corresponding transcript he predicts routine scans becoming commonplace; longitudinal-baseline benefits remain opinion/hypothesis, not new controlled outcomes. No distinct development rumor selected. Podcast census remains incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5

Galleri and organ-specific cancer screening

Coverage: focused_incomplete. 5 newly recorded entries.

Searches: Galleri EDCC October6 7 8 2026 poster results; cancer screening colorectal screening mammography trial first posted October2–9 2026; site:reddit.com Galleri October2026 after:2026-10-05 before:2026-10-10

Remaining gaps: Read current topic/state and September5 overlap; live API retrieved all six saved registries, including October6 Vanguard update. Registry administrative refresh is not a new results announcement.; Closed prior EDCC gap: appraised actual October6–7 sponsor PDFs for emergency routes, detection-window modeling, health equity, mammography adherence, cancer spectrum and stage-associated life-expectancy modeling. Exact hub posting dates retained separately from conference6–8 window.; Organ-specific breast/colorectal/lung/precancer programs received targeted discovery searches; not an exhaustive registry/publication census. FDA September23 panel follow-through and labels were not independently reappraised in full. Life-expectancy-by-stage modeling not promoted as observed screening survival benefit.

Informal sources and unresolved claims: Targeted original Reddit/Galleri and informal meeting searches did not yield a distinct attributable fresh rumor. This is a limited search, not proof there are no rumors; no inference of FDA approval from an advisory vote or poster.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14

GLP-1 and related metabolic therapies

Coverage: focused_incomplete. 5 newly recorded entries.

Searches: ClinicalTrials.gov interventional discovery, LastUpdatePostDate September 5–October 9; updated named records from current topic pages.; Dated official sponsor, regulator, trial/publication, conference and original informal-source searches, with October 7–9 prioritized after the October 6 review.

Remaining gaps: Window: September 5–October 9, 2026, retaining the seven-day overlap from the last full successful check on September 12. October 6 findings were deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; GLP1 broad discovery returned 767 records; first 100 downloaded; selected relevant records screened; pagination and a worldwide entrant, safety/hold, formulation/approval census remain incomplete. Raw named records refreshed without treating routine edits as news. Root owns October 1 COURAGE; cross-link rather than duplicate. ZUPREME-2 exact dose mapping and complete harms/estimand tables unreleased.

Informal sources and unresolved claims: Oct8 original SOLIS-1 self-report and Oct9 comments retrieved through indexed original thread after direct fetch failure. Pfizer official study page independently matches GLP-1+dual amylin/calcitonin mechanism, but patient identity, allocation and causal attribution cannot be verified. Prior EloraTZP near-30% rumor remains unconfirmed; no new formal matching readout recovered. Full EASD/podcast audio and source-chain census remain incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19
• Source 20
• Source 21
• Source 22
• Source 23

Muscle building and preservation

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: Official named-program registry refresh; paginated discovery September 5–October 9, 2026; Dated sponsor, regulator, paper and conference searches; original Reddit and selected podcast/interview leads

Remaining gaps: All saved named NCT records refreshed and all pages of official overlap discovery screened (23 returned records). Search starts September 5/6 from the last full successful check, not October 6 alone. Incidental matches excluded; literature, international registries, all regulatory files and complete podcast/audio appraisal remain incomplete.; BELIEVE full withdrawal tables and HOPE-3 extension adverse-event tables remain missing. The October 7 PPMD webpage is still an invitation; a third-party transcript indicates a discussion but no original replay was appraised, so its elapsed date is not a new numerical result.

Informal sources and unresolved claims: Read October 1 original NTNPerformance repost of the COURAGE release; it supplies no independent corroboration. A BiohackingU October 7 comment calls trevogrumab phase 3, but the original sponsor/registry specify phase 2; gray-market sourcing context excluded. Revisited the September 9 Cantor enobosarm direction via third-party transcript; no actual phase 3 initiation confirmed, original audio unreviewed, stable claim remains unconfirmed without repeat alert.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14

Longevity and healthspan trials

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: ClinicalTrials.gov interventional discovery, LastUpdatePostDate September 5–October 9; updated named records from current topic pages.; Dated official sponsor, regulator, trial/publication, conference and original informal-source searches, with October 7–9 prioritized after the October 6 review.

Remaining gaps: Window: September 5–October 9, 2026, retaining the seven-day overlap from the last full successful check on September 12. October 6 findings were deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; All 47 matches in the bounded longevity registry discovery were downloaded; broad terms still include disease-specific programs and not a comprehensive global geroscience census. Named RESTOR, MAVRIC, metformin/everolimus and IPACE-HIV records refreshed.; AFAR TAME official page retrieval failed again. Funded launch cannot be refreshed. Full original audio and complete mTOR/senolytic safety/publication census remain gaps.; Newly recovered TRUTH MASH trial belongs to liver; disease-specific biopsy response does not complete the longevity baseline or establish healthier/longer life.

Informal sources and unresolved claims: Revisited PEARL24month claim: newly located USA Longevity Today page asserts September 17 Nature Aging primary publication; direct page fetch failed, matching Nature Aging paper not located in exact search. This is another unconfirmed assertion, not independent corroboration of prior Vitaei claim; no repeat efficacy alert. Oct9 Futurology framing of MASH cure reviewed against original paper. Audio not fully reviewed.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16

Localized fat removal and cellulite

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: localized_fat: named programs and broader human-study discovery, September 5–October 9, with priority to October 6–9.; localized_fat: original Reddit posts, podcast/talk descriptions and unresolved saved informal claims.; Europe PMC FIRST_PDATE September 5–October 9 failed HTTP503; targeted web primary literature used as partial fallback.

Remaining gaps: Read the current assigned topic and canonical scope/state. Named original registry records refreshed; all pages of broad ClinicalTrials.gov discovery for September 5–October 9 were retrieved (205 records, with incidental matches excluded). This honors the seven-day overlap from the saved September 12 full successful check.; Europe PMC original-literature discovery again returned HTTP 503. Targeted primary publisher, sponsor and conference searches were performed, but the worldwide paper/regulator/procedure and original-audio census remains incomplete. Preserve last_successful_check_utc.; SUPREME-01 remains recruiting 320, last posted September 22; CBL-0206 records, AYP-101 completed/no results, tesamorelin and RZL-012 records retain saved status. Caliway index still ends with October 2 EASD report. No new SUPREME-02, China NDA filing or broader tesamorelin indication verified.; A newly posted Assiut 40-person double-chin cohort NCT07864246 is not yet recruiting and has only one broadly described group; no randomized modality comparison or result. Not promoted as efficacy. Full original CBL-514 EASD tables, cellulite comparative census and regulator/rare-harm review remain gaps.

Informal sources and unresolved claims: October 7 BodyHackGuide thread https://www.reddit.com/r/BodyHackGuide/comments/1wzmfif/down_30_on_rt_what_else_to_add/ and October 9 tesamorelin/blend discussion are self-experimentation, not formal-program outcomes or attributable development forecasts. Existing CBL-514 sourcing threads were deduplicated. No new rumor selected; full investor/podcast recordings incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18

Broad cardiovascular prevention, lipids and screening

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: ClinicalTrials.gov interventional discovery, LastUpdatePostDate September 5–October 9; updated named records from current topic pages.; Dated official sponsor, regulator, trial/publication, conference and original informal-source searches, with October 7–9 prioritized after the October 6 review.

Remaining gaps: Window: September 5–October 9, 2026, retaining the seven-day overlap from the last full successful check on September 12. October 6 findings were deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; Broad discovery returned 494 records; first 100 downloaded; selected relevant records screened. Remaining pages and a worldwide lipid/gene-editing/safety census not completed. Saved AMBIENCE, REFINE-CAC and DR10624 October 6 entries retained rather than repeated.; Curbsiders October 5 original show page recovered after the prior fetch gap. It discusses established 2026 lipid guidance and awaiting inclisiran outcomes, not a new trial readout. Full YouTube transcript/audio not appraised.

Informal sources and unresolved claims: Original Curbsiders episode #541, October 5, Daniel Edmundowicz: show notes reviewed; LDL-target jokes and vaccine analogy not converted into medical recommendations. No full transcript/timestamp appraisal; no new attributable development rumor from this page.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19
• Source 20
• Source 21
• Source 22

Alzheimer's screening and therapies

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: Alzheimer therapy biomarker bloodtest clinical trial October2026 after:2026-10-05 before:2026-10-10; SAR448851 NCT07688213 TREMHANCE phase2; site:reddit.com/r/Alzheimers October2026 trialtreatment; ALN-5288 October2026

Remaining gaps: Read current topic/state and September5 overlap; all12 saved registry records,32 new-study search matches and recovered SAR448851 live record appraised for scope.; SAR448851 registry access gap closed, historical start July28 retained as baseline. Selected new prevention vaccine registration. No new efficacy inferred from registry refreshes for ClarityAD/PDE4PET/ALN-5288.; All antibody labels/ARIA changes, assay recalls, worldwide prevention cohorts and full blood-test outcomes inventory remain incomplete. Several new biomarker/device records require full appraisal before promotion.

Informal sources and unresolved claims: Opened original Oct7–8 r/Alzheimers treatment-or-not thread. It mixes anonymous personal experiences, unsupported universal-treatment claims, and long-delay figures apparently derived from modeling; none establishes new randomized efficacy/safety or individual benefit. Existing Attia/Davidson obicetrapib prevention hypothesis remains unconfirmed. No distinct new development rumor selected.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17

Psilocybin and related therapies

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: psychedelic COMP360 HLP003 GH001 trial results October2026; site:reddit.com/r/shroomstocks October2026 APPROACH; APPROACH psilocybin NCT September28 2026 completion; psilocybin lysergide mebufotenin MDMA newly registered September5 October9 2026

Remaining gaps: Read current topic/state, September5 overlap and all six saved trial records;13 newly registered search matches screened for psychedelic rather than incidental DMT abbreviation.; Selected formal PMDD study, with phase1 safety endpoints and supervised exposure explicit. Nicotine NCT07852832 is a three-person basic-science pilot, not cessation efficacy; ADEPT NCT07833761 and PEARL NCT07820033 were discovery leads not fully appraised.; APPROACH NCT06564818 surfaced via original Reddit and registry mirror; its live primary record still needs refresh, so Sept4 actual-completion claim not promoted. FDA hearing full transcript/outcome, all COMP/GH/Helus/Definium safety and complete international registry sweep remain gaps.

Informal sources and unresolved claims: Original Oct5 shroomstocks weekly thread contains speculation based on APPROACH registry dates; actual completion is not a topline announcement and no efficacy inference is justified. Oct8 investing post repeats COMP360 approval timing hopes without inside source. No material confirmation of saved MDMA resubmission rumor. Broader full podcast/talk review incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10

Mental-health treatments, SSRIs and newer antidepressants

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: antidepressant anxiety OCD PTSD bipolar addiction clinical trial October2026 after:2026-10-05 before:2026-10-10; WELTRUZA October9 2026 FDA; site:reddit.com SSRI October2026 new trial

Remaining gaps: Read expanded diagnosis topic/state and saved19 registries. Appraised Oct9 Teva release plus actual45-page approved label for new olanzapine formulation, not an antidepressant claim.; New-study search returned100 with another page not retrieved; broad query contains many incidental depression/trauma terms. FEAST-AFT selected with active-comparator and primary quality-of-life endpoint preserved.; OCD/PTSD/anxiety/addiction/bipolar full pipeline, all SSRI long-term harms and formal label/guideline changes remain incompletely reviewed. WELTRUZA is included explicitly as schizophrenia/formulation-specific within broad mental-health treatment, without antidepressant/bipolar extrapolation.

Informal sources and unresolved claims: Targeted original Reddit and new-program informal searches performed. Oct9 WELTRUZA Reddit post traces to public approval release rather than a separate rumor. Older emotional-blunting anecdotes and fluoxetine-reanalysis commentary do not constitute new development signals. Full podcasts/Q&A census incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19
• Source 20
• Source 21
• Source 22
• Source 23
• Source 24

Bone health, joint preservation and cartilage repair

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: Official named-program registry refresh; paginated discovery September 5–October 9, 2026; Dated sponsor, regulator, paper and conference searches; original Reddit and selected podcast/interview leads

Remaining gaps: All saved named NCT records refreshed and all pages of official overlap discovery screened (96 returned records). Search starts September 5/6 from the last full successful check, not October 6 alone. Incidental matches excluded; literature, international registries, all regulatory files and complete podcast/audio appraisal remain incomplete.; No new ACTiVION-I October topline or lorecivivint regulatory decision verified. Cartilage-cell and osteoporosis programs refreshed in registries; complete fracture/sequencing literature remains incomplete. EB613 October 9/11 ASBMR slots were recovered from an August announcement; no new efficacy inferred before presentation.

Informal sources and unresolved claims: Original Osteoarthritis Reddit discovery returned recycled lorecivivint/sprifermin forecasts and injection anecdotes rather than a dated new formal-development claim. Broad original podcast review remains a gap.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19

Liver health and noninvasive assessment

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: ClinicalTrials.gov interventional discovery, LastUpdatePostDate September 5–October 9; updated named records from current topic pages.; Dated official sponsor, regulator, trial/publication, conference and original informal-source searches, with October 7–9 prioritized after the October 6 review.

Remaining gaps: Window: September 5–October 9, 2026, retaining the seven-day overlap from the last full successful check on September 12. October 6 findings were deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; Liver discovery returned 171 records; first 100 downloaded; selected relevant records screened, remaining page not reviewed. Updated saved RNA-interference protocols rechecked. September 29 TRIUMPH-1 full methods/CI access gap and worldwide noninvasive-screening/approval coverage remain.

Informal sources and unresolved claims: October 9 original r/Futurology post located: https://www.reddit.com/r/Futurology/comments/1x1lwvz/in_a_world_first_in_a_phase_2_trial_with_31/ . It frames histologic MASH resolution as a 50+% cure rate; original trial supports a short-term biopsy outcome, not proven durable cure. This is interpretation of a published paper, not a new clinical leak. Wider podcast audio and existing European Wegovy-MASH rumor not comprehensively refreshed.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15

Cancer treatment, vaccines and recurrence prevention

Coverage: focused_incomplete. 4 newly recorded entries.

Searches: cancer vaccine ADC radiopharmaceutical newly registered October2–9 2026; NRG-BR002 October7 2026 metastasis directed trial; site:ir.sellaslifesciences.com REGAL October2026 80 events; site:reddit.com cancer vaccine October2026 REGAL

Remaining gaps: Read broad oncology topic/state, September5 overlap, registry collection and Oct2–9 new-study discovery. No duplicate evERA, IMpassion050, daraxonrasib, belzutifan/lenvatinib or prior vaccine schedule events.; Appraised Oct7 MDAnderson NRG-BR002 investigator report; journal full paper and primary PubMed page inaccessible. Detailed hazard ratios from secondary abstract mirrors are deliberately omitted pending primary access.; BNT122-01 source conflict: Aug28 BioNTech discontinuation/futility/OS-imbalance statement versus Oct7 NCT04486378 active-not-recruiting record with November2026 estimate. Do not infer resumed treatment from registry. Broad cellular/radiopharmaceutical and global oncology census remains incomplete; all treatment-line safety labels not refreshed.

Informal sources and unresolved claims: Revisited October2 REGAL any-day event80 speculation and official August11 sponsor release. No new official confirmation of event80 or topline result found in focused searches; retain unconfirmed and do not re-alert. Event accrual cannot identify randomized-arm survival or predict approval. Full investor-call/audio sweep remains incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19
• Source 20
• Source 21
• Source 22
• Source 23
• Source 24
• Source 25
• Source 26
• Source 27
• Source 28
• Source 29
• Source 30
• Source 31

Autoimmune disease and immune reset

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: Official named-program registry refresh; paginated discovery September 5–October 9, 2026; Dated sponsor, regulator, paper and conference searches; original Reddit and selected podcast/interview leads

Remaining gaps: All saved named NCT records refreshed and all pages of official overlap discovery screened (28 returned records). Search starts September 5/6 from the last full successful check, not October 6 alone. Incidental matches excluded; literature, international registries, all regulatory files and complete podcast/audio appraisal remain incomplete.; No matched rap-cel/zola-cel restart announcement verified; pre-pause or unchanged recruiting labels do not prove restart. Full CAR-T longer-term safety, ACR abstract census, FB102 protocol and litifilimab arm-level tables remain gaps.

Informal sources and unresolved claims: Read original OncLive September22 discussion of Mount Sinai IBD CAR-T planning; no matched newly initiated study verified, existing stable claim remains unconfirmed. Read lupus/scleroderma Reddit anecdotes and discussions; unverified identity, selected responders and unsupported safety rankings mean no comparative or cure result. Full podcast recordings unreviewed.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19

Non-opioid pain treatments

Coverage: focused_incomplete. 3 newly recorded entries.

Searches: Official named-program registry refresh; paginated discovery September 5–October 9, 2026; Dated sponsor, regulator, paper and conference searches; original Reddit and selected podcast/interview leads

Remaining gaps: All saved named NCT records refreshed and all pages of official overlap discovery screened (49 returned records). Search starts September 5/6 from the last full successful check, not October 6 alone. Incidental matches excluded; literature, international registries, all regulatory files and complete podcast/audio appraisal remain incomplete.; Broad trial discovery also located NIH experimental-pain HNK and another rotator-cuff suzetrigine study, not promoted as patient efficacy. Full VX-993 and other chronic-pain safety, surgery abstracts and international records remain incompletely appraised.

Informal sources and unresolved claims: Read original r/anesthesiology Journavx thread. Anonymous clinician/patient accounts conflict on relief and opioid substitution; mixed regimens, uncontrolled samples and unverified insurance claims are not trial outcomes or reliable coverage estimates. No distinctive formal-development rumor selected; full Radiolab/podcast audio not appraised.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18

Kidney preservation and earlier detection

Coverage: focused_incomplete. 3 newly recorded entries.

Searches: ClinicalTrials.gov interventional discovery, LastUpdatePostDate September 5–October 9; updated named records from current topic pages.; Dated official sponsor, regulator, trial/publication, conference and original informal-source searches, with October 7–9 prioritized after the October 6 review.

Remaining gaps: Window: September 5–October 9, 2026, retaining the seven-day overlap from the last full successful check on September 12. October 6 findings were deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; Kidney discovery returned 330 records; first 100 downloaded; selected relevant records screened, remainder not completed. Existing REMODEL null primary outcomes, combination registrations and SCD-PED conference milestone retained rather than repeated. Farabursen full registry not reconciled. PYC-003 exact kidney-volume plotted values unavailable numerically; no visual digitization performed.

Informal sources and unresolved claims: Original August 9 ADPKD thread, updated October 8, reviewed via indexed comments; Tufts recruitment claim cross-checked at investigator site. Older nephrologist messages are secondhand and conflict on timing. No clinically reliable efficacy inference drawn. Broader kidney podcast/talk transcripts remain incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19
• Source 20
• Source 21
• Source 22

Hearing and vision preservation/restoration

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: EURETINA October2026 retinal late breaking BEST1 MCO010 PST611 results; 4SIGHT 4D150 October2026 SPECTRA phase3; site:reddit.com AC102 October2026 hearing trial; hearing loss macular degeneration retinal gene therapy newly registered October2–9 2026

Remaining gaps: Read current topic/state and September5 overlap. All13 saved registry records plus10 newly registered matches retrieved. Recovered Sept28 4DMT primary release, corroborated new Oct9 4SIGHT record; no duplicate PRIMA36month or MOGENRY priority-review announcements.; Official EURETINA final-session/late-breaking reporting opened. New 4D150 DME findings have primary sponsor counts; PST611 qualitative summary is not an exact efficacy table. PRIMA conference-summary threshold differs from sponsor release and was not silently substituted.; BEST1 fullPDF retried through web and direct network, still403. Actual MCO010 acquired GA tables/trial match, PST611 tables and full DAYBREAK/BRUNELLO safety intervals remain gaps. Hearing acquired-loss inventory not fully refreshed.

Informal sources and unresolved claims: Original Oct2 investigator interview by ArshadKhanani discusses SPECTRA/4SIGHT, corroborating the public sponsor development announcement, not proving larger-trial safety. AC102 purported August29 email claim remains unconfirmed; live NCT05776459 retains January16 snapshot with elapsed February/July completion estimates, no posted results. No phase3/tinnitus launch inferred. Wider podcast sweep incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19
• Source 20
• Source 21

Hair loss, restoration and graying

Coverage: focused_incomplete. 3 newly recorded entries.

Searches: hair_loss: named programs and broader human-study discovery, September 5–October 9, with priority to October 6–9.; hair_loss: original Reddit posts, podcast/talk descriptions and unresolved saved informal claims.; Europe PMC FIRST_PDATE September 5–October 9 failed HTTP503; targeted web primary literature used as partial fallback.

Remaining gaps: Read the current assigned topic and canonical scope/state. Named original registry records refreshed; all pages of broad ClinicalTrials.gov discovery for September 5–October 9 were retrieved (200 records, with incidental matches excluded). This honors the seven-day overlap from the saved September 12 full successful check.; Europe PMC original-literature discovery again returned HTTP 503. Targeted primary publisher, sponsor and conference searches were performed, but the worldwide paper/regulator/procedure and original-audio census remains incomplete. Preserve last_successful_check_utc.; AWAKEN October 7 changes did not alter the saved recruitment/start/phase/size milestones, so no duplicate recruitment alert. Clascoterone, HEADLINE, VDPHL01, GT20029 and BioCopper named records retain status. Full current Kintor/Veradermics global guidance, every AA regulator/label and rare-harm census incomplete.; New Olistic retrospective female-pattern-hair-loss NCT07862374 and telogen-effluvium NCT07869199 are planned/review records without outcomes, with retrospective design but future registry schedule; not promoted as randomized benefit. FB102 October 8 celiac release is owned by autoimmune; vitiligo/AA references do not add a new hair result.

Informal sources and unresolved claims: Reopened BioQ and original ToastedCaffeine Reddit post: BQ-002 existence is corroborated, but candidate-specific human trial and 2027 start remain unconfirmed. Cosmo still forecasts Q1 2027 U.S. filing, not launch; saved late-2027/2028 community inference is unchanged. October 6 PP405 https://www.reddit.com/r/tressless/comments/1wz35hi/pp405_phase_23_study_has_begun/ repeats a saved registry milestone. October 9 pipeline hopes https://www.reddit.com/r/tressless/comments/1x1fxgm/are_you_hopeful_for_the_potential_future/ add speculative timing, not a new attributable formal event. No repeat rumor alert. Full audio/transcripts incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19
• Source 20
• Source 21
• Source 22
• Source 23
• Source 24

Skin aging, laxity and regeneration

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: skin_aging: named programs and broader human-study discovery, September 5–October 9, with priority to October 6–9.; skin_aging: original Reddit posts, podcast/talk descriptions and unresolved saved informal claims.; Europe PMC FIRST_PDATE September 5–October 9 failed HTTP503; targeted web primary literature used as partial fallback.

Remaining gaps: Read the current assigned topic and canonical scope/state. Named original registry records refreshed; all pages of broad ClinicalTrials.gov discovery for September 5–October 9 were retrieved (41 records, with incidental matches excluded). This honors the seven-day overlap from the saved September 12 full successful check.; Europe PMC original-literature discovery again returned HTTP 503. Targeted primary publisher, sponsor and conference searches were performed, but the worldwide paper/regulator/procedure and original-audio census remains incomplete. Preserve last_successful_check_utc.; KB304 remains active/not recruiting with stale 2025 completion estimate; no Phase 2 actual initiation verified. Ellacor nine-person completed/no-results cohort and AnteAGE pilot registrations already captured October 6. FDA RF-microneedling communication remains older ongoing evaluation, not relabeled a new alert.; Sofwave June paper full text redirected to abstract; October 5 sponsor promotion deduplicated by actual paper date. September 22 multimodal RF RCT full appraisal and world device clearance/rare-complication census remain incomplete. PRX S acne-prone skin NCT07866131 is an observational cosmetic protocol, no outcome.

Informal sources and unresolved claims: October 6 Vitality Unfiltered David Bauder/Alicia Sanderson episode https://www.buzzsprout.com/2542776/episodes/19774930-sofwave-non-surgical-skin-tightening-collagen-facial-rejuvenation-with-alicia-sanderson-md?t=0 was found as original show description. It concerns existing procedures, not a verified new trial milestone; full audio/transcript not reviewed. Earlier Lufkin/Durairaj rapalog/GLP-1-face lead remains unappraised. No new rumor selected.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12

Scar prevention, treatment and stretch marks

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: scars: named programs and broader human-study discovery, September 5–October 9, with priority to October 6–9.; scars: original Reddit posts, podcast/talk descriptions and unresolved saved informal claims.; Europe PMC FIRST_PDATE September 5–October 9 failed HTTP503; targeted web primary literature used as partial fallback.

Remaining gaps: Read the current assigned topic and canonical scope/state. Named original registry records refreshed; all pages of broad ClinicalTrials.gov discovery for September 5–October 9 were retrieved (182 records, with incidental matches excluded). This honors the seven-day overlap from the saved September 12 full successful check.; Europe PMC original-literature discovery again returned HTTP 503. Targeted primary publisher, sponsor and conference searches were performed, but the worldwide paper/regulator/procedure and original-audio census remains incomplete. Preserve last_successful_check_utc.; SCARFREE still not yet recruiting, with October 2026/August–November 2028 estimates already captured. Geneva verteporfin and siSPARC remain stale/not-yet-recruiting or unknown. October 1 Syntara expansion and local-reaction/null clinical findings were deduplicated.; New October 3 CO2-versus-microplasma-RF hypertrophic-scar abstract PMID42828438 has domain-specific short-term changes but lacks participant count and co-primary score effects; full paper appraisal remains a gap, no broad efficacy/zero-harm claim. October 9 retrospective disclosure NCT07868445 lists a completed 30-person laser/exosome-versus-HA acne-scar study with June–September 2025 dates and no posted results; narrative superiority wording was not treated as an outcome table. Full stretch-mark and rare-harm census incomplete.

Informal sources and unresolved claims: Saved August26 r/verteporfin https://www.reddit.com/r/verteporfin/comments/1vypnsk/verteporfin_status_upcoming_trials_and/ and recent formal-trial searches found no new documented dosing/efficacy claim. Unregulated/off-label self-experimentation and anecdotes were not converted into trial outcomes. Full investor recordings and podcast originals incomplete; no new rumor selected.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16

Facial volume restoration and contour

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: facial_volume: named programs and broader human-study discovery, September 5–October 9, with priority to October 6–9.; facial_volume: original Reddit posts, podcast/talk descriptions and unresolved saved informal claims.; Europe PMC FIRST_PDATE September 5–October 9 failed HTTP503; targeted web primary literature used as partial fallback.

Remaining gaps: Read the current assigned topic and canonical scope/state. Named original registry records refreshed; all pages of broad ClinicalTrials.gov discovery for September 5–October 9 were retrieved (107 records, with incidental matches excluded). This honors the seven-day overlap from the saved September 12 full successful check.; Europe PMC original-literature discovery again returned HTTP 503. Targeted primary publisher, sponsor and conference searches were performed, but the worldwide paper/regulator/procedure and original-audio census remains incomplete. Preserve last_successful_check_utc.; Macrofat NCT07805889 recruiting 400 and GLP1-Radiesse recruiting/no results retain status. HArmonyCa completion and new Facetem/Radiesse registrations already recorded October 6. No new comparative efficacy selected.; Full new-filler FDA/overseas inventory, precise launch inventory, rare delayed harms and post-weight-loss randomized efficacy remain incomplete. Existing HA-collagen reporting discrepancy not resolved.

Informal sources and unresolved claims: October9 https://www.reddit.com/r/PlasticSurgery/comments/1x1lv4i/fat_grafting_failed_renuva_vs_sculptra_for/ describes personal graft-survival experience and requests alternatives; not a formal trial or general incidence. Recent Secret Services podcast descriptions and saved Lufkin/Durairaj episode do not supply a verified new named-program claim; recordings/transcripts not appraised. Adipeau promotion remains distinct from its already saved uncontrolled pilot. No new rumor selected.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12

Pigmentation and uneven skin tone

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: pigmentation: named programs and broader human-study discovery, September 5–October 9, with priority to October 6–9.; pigmentation: original Reddit posts, podcast/talk descriptions and unresolved saved informal claims.; Europe PMC FIRST_PDATE September 5–October 9 failed HTTP503; targeted web primary literature used as partial fallback.

Remaining gaps: Read the current assigned topic and canonical scope/state. Named original registry records refreshed; all pages of broad ClinicalTrials.gov discovery for September 5–October 9 were retrieved (53 records, with incidental matches excluded). This honors the seven-day overlap from the saved September 12 full successful check.; Europe PMC original-literature discovery again returned HTTP 503. Targeted primary publisher, sponsor and conference searches were performed, but the worldwide paper/regulator/procedure and original-audio census remains incomplete. Preserve last_successful_check_utc.; STOP-V1/V2, DelVito and FXS5626 saved status retained; no new registry results. October 1 Viti-Up extension/phototherapy sponsor data deduplicated. Incyte actual EADV P2467/P1780/P2463 posters remain a retrieval gap.; No full melasma/PIH/solar-lentigine trial or regulator census. KT939 matched protocol/current cosmetic submission status still unresolved. October 8 maturational-hyperpigmentation characterization is not a treatment readout.

Informal sources and unresolved claims: October7 https://www.reddit.com/r/Vitiligo/comments/1x01ejq/11_yr_old_daughter_with_vitiligo_question_about/ includes an anonymous long-term povorcitinib participant anecdote and generalized safety assertions, not blinded outcome data or approval confirmation. October6 r/Scholar request for a 2025 tranexamic-acid review is a repost/access request, not fresh data. Saved melasma podcast remains descriptive with no new attributable forecast; full audio not reviewed.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11

Acne and rosacea

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: acne_rosacea: named programs and broader human-study discovery, September 5–October 9, with priority to October 6–9.; acne_rosacea: original Reddit posts, podcast/talk descriptions and unresolved saved informal claims.; Europe PMC FIRST_PDATE September 5–October 9 failed HTTP503; targeted web primary literature used as partial fallback.

Remaining gaps: Read the current assigned topic and canonical scope/state. Named original registry records refreshed; all pages of broad ClinicalTrials.gov discovery for September 5–October 9 were retrieved (52 records, with incidental matches excluded). This honors the seven-day overlap from the saved September 12 full successful check.; Europe PMC original-literature discovery again returned HTTP 503. Targeted primary publisher, sponsor and conference searches were performed, but the worldwide paper/regulator/procedure and original-audio census remains incomplete. Preserve last_successful_check_utc.; SP0268 vaccine, remibrutinib PPR and redness-study records refreshed; no new posted outcomes. Denifanstat Chinese extension already reported September 30 and not treated as a new Oct9 efficacy result.; New PRX S observational cosmetic record NCT07866131 and retrospective exosome-acne-scar disclosure noted without efficacy inference; scar repair belongs to scars. Full rosacea ocular/flushing/vessel and antibiotic-resistance/label/device census incomplete. Sagimet full October9 release blocked403, indexed primary clinical-development wording checked against complete registry.

Informal sources and unresolved claims: Targeted October6–9 Reddit and original talk/podcast queries did not recover a noteworthy new AURORA/B244/SP0268 rumor. Sagimet Fall Clinical/replay descriptions are sponsor context, not full Q&A verification. Earlier UK Finacea shortage anecdote was not generalized to U.S. availability; no manufacturer confirmation. Full recorded discussions incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16

Dental alignment, regeneration and repair

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: dental: named programs and broader human-study discovery, September 5–October 9, with priority to October 6–9.; dental: original Reddit posts, podcast/talk descriptions and unresolved saved informal claims.; Europe PMC FIRST_PDATE September 5–October 9 failed HTTP503; targeted web primary literature used as partial fallback.

Remaining gaps: Read the current assigned topic and canonical scope/state. Named original registry records refreshed; all pages of broad ClinicalTrials.gov discovery for September 5–October 9 were retrieved (288 records, with incidental matches excluded). This honors the seven-day overlap from the saved September 12 full successful check.; Europe PMC original-literature discovery again returned HTTP 503. Targeted primary publisher, sponsor and conference searches were performed, but the worldwide paper/regulator/procedure and original-audio census remains incomplete. Preserve last_successful_check_utc.; P11-4 official abstract https://sciforum.net/paper/34045 remains the same October2 material already appraised; conference October7–9 does not prove extra results or actual delivery. Direct printed-aligner September24 publication and registry status deduplicated. NCT07496892 still not yet recruiting with stale elapsed estimates; OrthoPulse status unchanged.; Toregem news now has October6 BioJapan business presence but no PhaseIIa first dosing/results verification. Japanese original jRCT matched PhaseIIa and complete PhaseI numerical safety remain unresolved. Numerous new October6–9 retrospective/historical bracket-bonding, mouthrinse, pulpotomy and movement records lack outcomes; their registration was not relabeled as new demonstrated clinical benefit. Full alignment/root/gum/final-bite/retention and new-tooth/repair census remains incomplete.

Informal sources and unresolved claims: Saved https://www.reddit.com/r/Biohackers/comments/1wq1adh/910_dentists_probably_wont_recommend_this/ and October4 https://www.reddit.com/r/ITOI/comments/1wxkmlv/japan_is_trialing_a_drug_that_regrows_human_teeth/ repeat older TRG035/2030 expectations and extrapolate to acquired missing teeth. No new controlled human result or verified phaseIIa dose followed. Fresh comment activity is not independent confirmation. No new rumor selected; full orthodontic/tooth-regrowth recordings not appraised.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15

Allergy and airway disease

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: Official named-program registry refresh; paginated discovery September 5–October 9, 2026; Dated sponsor, regulator, paper and conference searches; original Reddit and selected podcast/interview leads

Remaining gaps: All saved named NCT records refreshed and all pages of official overlap discovery screened (131 returned records). Search starts September 5/6 from the last full successful check, not October 6 alone. Incidental matches excluded; literature, international registries, all regulatory files and complete podcast/audio appraisal remain incomplete.; No fuller rademikibart acute-COPD absolute-count/CI/harms table or verified VIASKIN filing acceptance/action date recovered. Food/environmental allergy and sinus literature remain incomplete; no approval inferred from submission.

Informal sources and unresolved claims: Reddit rademikibart/VIASKIN and allergy podcast discovery mainly surfaced known sponsor readout/submission reposts and personal treatment experience. No independent new development rumor selected. Original conference audio and broader seasonal/sinus informal survey remain unappraised.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16

Infectious-disease prevention and treatment

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: Official named-program registry refresh; paginated discovery September 5–October 9, 2026; Dated sponsor, regulator, paper and conference searches; original Reddit and selected podcast/interview leads

Remaining gaps: All saved named NCT records refreshed and all pages of official overlap discovery screened (312 returned records). Search starts September 5/6 from the last full successful check, not October 6 alone. Incidental matches excluded; literature, international registries, all regulatory files and complete podcast/audio appraisal remain incomplete.; VAX-31 topline and earlier PLG0206/China RSV/TNP2092 events already saved and deduplicated. No actual STEPS-CF first dosing verified. Broader new-antibiotic human efficacy, regulator files, conference abstracts and long-acting infection-prevention census remain incomplete. Gepotidacin resistance paper has September 1 online date despite October issue; not relabeled new October news.

Informal sources and unresolved claims: Located Communicable E64 (October4, Emily McDonald/Marc Bonten with Sylvain Lother/Valentijn Schweitzer) and Children’s Colorado Charting Pediatrics October6 show notes. These discuss existing antibiotic evidence/ stewardship rather than a new-development claim; full audio unreviewed. Read original personalized-phage-guideline Reddit discussion; expert consensus is not randomized efficacy. No separate noteworthy new rumor selected.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19
• Source 20

Genetic screening and risk prediction

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: Universal germline genetic testing cancer October8 2026 Stadler 39184; genomic screening polygenic pharmacogenomic embryo selection newly registered September6 October9 2026; site:mynucleus.com Vitruvian October2026 trialresults; site:reddit.com genetic screening October2026

Remaining gaps: Read current topic/state and September6 overlap. All seven saved registries and new-registration discovery retrieved. PGT-P NCT07841769 remains not yet recruiting in Sept25 record after its Oct1 estimated start; actual start unverified.; Appraised official Oct8 AACR/MSK germline-study reports and Oct6 Yale planned prospective project. Primary germline full paper failed403; PubMed unavailable and EuropePMC not yet indexed. Do not claim full paper/supplement appraisal.; PGT-M/SR/A guidance, newborn genomic screening and pharmacogenomics were not comprehensively refreshed. New FOCUS Sept8 population-genomic implementation registry was located, but inconsistent site/sample counts require detailed follow-up before promoting it.

Informal sources and unresolved claims: Revisited original Nucleus/Vitruvian source chain and sponsor September whitepaper. Five-embryo top-versus-bottom10.8IQ and ten-embryo14.3IQ are model projections with predominantly European-ancestry sibling validation; not observed offspring outcomes or top-versus-average gain. Original X remains inaccessible. No new confirmation/retraction found; leave existing rumor unconfirmed without repeat alert.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16

Insomnia

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: ClinicalTrials.gov interventional discovery, LastUpdatePostDate September 5–October 9; updated named records from current topic pages.; Dated official sponsor, regulator, trial/publication, conference and original informal-source searches, with October 7–9 prioritized after the October 6 review.

Remaining gaps: New condition baseline remains incomplete. Reviewed inherited hub, preceding 90-day development leads and selected older pivotal/contextual sources; October 6 findings deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; Broad insomnia discovery returned 673 records, first 100 downloaded; selected relevant records screened; much incidental oncology/psychiatry symptom language remains. Older drug label, CBT-I/digital durability and sleep-architecture safety census incomplete. Prior DARI-DREAM and COMISA-PEC not re-reported.

Informal sources and unresolved claims: Oct8 SOLIS-1 participant self-report and Oct2 Eloralintide weekly-trial posts contain insomnia/fatigue anecdotes; no population safety estimates or independent insomnia-drug milestone inferred. Original insomnia podcast/talk transcripts incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6

Obstructive sleep apnea

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: ClinicalTrials.gov interventional discovery, LastUpdatePostDate September 5–October 9; updated named records from current topic pages.; Dated official sponsor, regulator, trial/publication, conference and original informal-source searches, with October 7–9 prioritized after the October 6 review.

Remaining gaps: New condition baseline remains incomplete. Reviewed inherited hub, preceding 90-day development leads and selected older pivotal/contextual sources; October 6 findings deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; All 66 matches in the bounded OSA discovery were downloaded; selected relevant records screened, plus saved registries. It is not a full older PAP/oral-appliance/surgical/device-validation baseline. Sleep outcomes versus cardiovascular outcomes retained separately.

Informal sources and unresolved claims: Targeted apnea drug/device rumor searches did not yield a new original development claim promoted in this bounded review. Full Oct2 AADSM podcast recording and older device-access/insurance anecdotes not appraised.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6

Narcolepsy & excessive sleepiness

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: ClinicalTrials.gov interventional discovery, LastUpdatePostDate September 5–October 9; updated named records from current topic pages.; Dated official sponsor, regulator, trial/publication, conference and original informal-source searches, with October 7–9 prioritized after the October 6 review.

Remaining gaps: New condition baseline remains incomplete. Reviewed inherited hub, preceding 90-day development leads and selected older pivotal/contextual sources; October 6 findings deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; All 13 matches in the bounded hypersomnolence discovery downloaded; selected relevant records screened. Saved orexin protocols refreshed. Established oxybate/stimulant/pitolisant/solriamfetol full labeling/safety and whole-world baseline remain incomplete.; Official Orzeyful page retains expected-by-November availability conditional on DEA scheduling. No completed official DEA scheduling action established; do not imply launch.

Informal sources and unresolved claims: Original Oct7 r/Narcolepsy thread contains anonymous patient participation in an orexin trial, not a new official recruitment/readout milestone. Sponsor conditional Orzeyful forecast checked; full talk/audio not reviewed.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10

Circadian rhythm disorders

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: ClinicalTrials.gov interventional discovery, LastUpdatePostDate September 5–October 9; updated named records from current topic pages.; Dated official sponsor, regulator, trial/publication, conference and original informal-source searches, with October 7–9 prioritized after the October 6 review.

Remaining gaps: New condition baseline remains incomplete. Reviewed inherited hub, preceding 90-day development leads and selected older pivotal/contextual sources; October 6 findings deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; Circadian broad query returned 154 records; first 100 downloaded; selected relevant records screened, remainder incomplete, with many incidental/mechanistic and oncology timing matches. Timed light/dark and melatonin disorder-specific sustained phase/function baseline remains incomplete.; Tasimelteon jet-lag hearing outcome/date not verified. Searches still locate June 3 notice and elapsed July 20 prehearing plan; no conclusion inferred. Saved DSWPD and SUSTAIN registry milestones preserved as estimates; no new result found in those specific records.

Informal sources and unresolved claims: Original October 2 r/DSPD discussion and October4/5 comments reviewed through indexed text: individual timing/medicine/light experiences, no attributable new formal trial result or development leak. No broad efficacy conclusion from anecdotes; full podcast/talk appraisal remains incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6

Restless legs syndrome

Coverage: focused_incomplete. 3 newly recorded entries.

Searches: ClinicalTrials.gov interventional discovery, LastUpdatePostDate September 5–October 9; updated named records from current topic pages.; Dated official sponsor, regulator, trial/publication, conference and original informal-source searches, with October 7–9 prioritized after the October 6 review.

Remaining gaps: New condition baseline remains incomplete. Reviewed inherited hub, preceding 90-day development leads and selected older pivotal/contextual sources; October 6 findings deduplicated.; 93 named NCT records across the ten topics and ten discovery queries downloaded successfully through the ClinicalTrials.gov public API. Download is not a claim that all fields/safety/results were exhaustively appraised.; Focused review only. Do not advance full successful-check timestamps or label incomplete remaining searches as no news.; All seven matches in bounded RLS discovery downloaded; selected relevant records screened. Selected older trial/guideline anchors added; full drug/iron labeling, safety, pediatric/pregnancy and older trial corpus remain incomplete. Venous-ablation full methods/harms gap persists; no cure conclusion.

Informal sources and unresolved claims: Original October 7 RLS algorithm thread led to a verified May 26 original publication. Individual October device/medication experiences are not trial efficacy. Full SLEEP/SOS recordings and podcast interviews remain incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10

Homepage review and public edition

The October 3 EloraTZP feature is retained after six days: it presents a recent active-comparator trial with matching-arm tolerability. New result ranges without dose mapping or analysis details are not converted into invented plotted points. Historical curves, intervals, trial populations and source dates remain unchanged. A background run skips user-facing browser handoff; release checks and native publication status are separate from browser QA. The publication receipt is recorded in state.json only after success.